INFORMATION ON THIS SITE IS ONLY INTENDED FOR NON-US HEALTHCARE PROFESSIONALS

Warning!

For healthcare professionals only

You are viewing the Novo Nordisk Virtual platform, provided to non-US health care professionals from around the world. By accessing this site and materials you accept this legal notice and expressly confirm your status as a healthcare professional.

 

This site is not country-specific and therefore may contain information which is not applicable to your country. Therefore, before prescribing any product, always refer to local materials such as the prescribing information and/or the Summary of Product Characteristics.

 

This site is not intended to provide medical advice and/or treatment guidance. Novo Nordisk accepts no liability for the accuracy, completeness or use of the information, and disclaims any liability to update the information contained on this site.

  1. Diabetes

    Discovering new and better ways to improve the life for people living with type 1 or type 2 diabetes.

100 years of driving change for people living with diabetes

We've been doing it for generations, pioneering change to improve diabetes care. Explore the latest research and innovation within diabetes below.

Disease information

Explore the latest knowledge about diabetes

An early SHIFT in treatment could change lives

An early SHIFT in treatment could change lives

When it comes to treating type 2 diabetes, there are more options available than ever before. But a SHIFT in treatment towards early and intensive HbA1c control can reduce the risks associated with type 2 diabetes and help your patients avoid long term complications.1-3
Understanding GLP-1

Understanding GLP-1

Learn what GLP-1 is, how it works in the body, and why it is important.
ASCVD in type 2 diabetes

ASCVD in type 2 diabetes

Atherosclerosis is the predominant cause of CVD and death in people with type 2 diabetes.
Time in Range

Time in Range

Time in Range is a new clinical metric within diabetes management that complements HbA1c providing a more complete picture of daily glucose levels.
Diabetes What's Next?

Diabetes What's Next?

Help your patients navigate life with diabetes.

Featured event

Diabetes event

Extend your EASD 2024 experience

Extend your EASD 2024 experience

Keep learning, also after the congress ends. Continue to discover the latest news from EASD 2024 and stay ahead of the curve in your field.

PRODUCTS

Our diabetes medicines and digital health solutions

▼Awiqli® is finally here

Awiqli® is finally here

It’s time to reinvent the basal insulin start experience with Awiqli® - the world’s first once-weekly basal insulin.

Rybelsus thumbnail

RYBELSUS® - The only type 2 diabetes pill of its kind4

RYBELSUS® (semaglutide tablets) is the only GLP-1 RA in a pill, which can deliver HbA1c reduction with the added benefit of weight loss, helping your patients to reduce the risk of long-term complications associated with type 2 diabetes.4-7
  1. Digital Health solutions

    As an increasing number of people worldwide are living with diabetes, our device and digital therapeutic innovations have the potential to support diabetes management.

You might also be interested in

5K Run/Walk

The 5K Virtual Challenges bring together people across the globe to emphasize the need for increased physical activity to help prevent diabetes and diabetes complications. This disease awareness activity provides participants with the opportunity to raise public awareness about the importance of a healthy lifestyle in preventing and controlling diabetes.

Team Novo Nordisk

Explore how the dedicated athletes and medical professionals of Team Novo Nordisk strive to inspire, educate, and empower those affected by diabetes, and set a new standard for living well with diabetes.

References

1.

Dalsgaard N, Vilsbøll T, Knop FK. Effects of glucagon-like peptide receptor agonists on cardiovascular risk factors: A Narrative review of head-to-head comparisons. Diabetes Obes Metab. 2018;20;508-19

2.

Nauck MA,, Quast DR, Wefers J. et al. GLP-1 receptor agonists in the treatment of type 2 diabetes – state-of-the-art. Mol Metab. 2021;46:101-102

References

1.

Dalsgaard N, Vilsbøll T, Knop FK. Effects of glucagon-like peptide receptor agonists on cardiovascular risk factors: A Narrative review of head-to-head comparisons. Diabetes Obes Metab. 2018;20;508-19

2.

Nauck MA,, Quast DR, Wefers J. et al. GLP-1 receptor agonists in the treatment of type 2 diabetes – state-of-the-art. Mol Metab. 2021;46:101-102

WE SEE THAT YOU ARE BROWSING FROM UNITED STATES. TO LEAVE CONGRESSHUB AND GO TO THE LOCAL HCP PORTAL, CLICK HERE